test-1025-1.pdf
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 1601 - 1610 ee natiijooyinka 3167
Bixiye
QP88-23 MCG Care Guidelines Transparency Tool Available via Availity Essentials by October 27, 2023
Taariikhda uu dhaqangalayo barnaamijka: Okt 25, 2023
Bixiye
QP85-23 MHCP Pharmacy Benefit Exclusion for Beyfortus™, Daxxify®, Elrexfio™, Izervay™, Talvey™, and Veopoz™
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Bixiye
QP86-23 MHCP Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective November 1, 2023
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Bixiye
QP87-23 Availity Essentials Updated Claim Entry Forms
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Bixiye
QP80-23 Blue Cross Response to Medical Oncology Drug Shortage of Cisplatin and Carboplatin
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Bixiye
QP81-23 Update: Medical Drug Update for Tofersen (Qalsody), Delandistrogene Moxeparvovec (Elevidys), and Donislecel (Lantidra)
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Bixiye
QP82-23 Commercial Pharmacy Benefit Exclusion for Beyfortus™, Daxxify®, Izervay™, and Veopoz™
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Bixiye
QP83-23 Commercial Pharmacy Benefit Exclusion for Budesonide-Formoterol Aerosol Inhaler and Tiotropium Bromide Inhalation Capsule
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Bixiye
QP84-23 Commercial Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective December 1, 2023
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023